Back to top
more

Doximity (DOCS)

(Delayed Data from NYSE)

$75.12 USD

75.12
1,364,908

+0.72 (0.97%)

Updated Sep 29, 2025 04:00 PM ET

After-Market: $75.14 +0.02 (0.03%) 6:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (63 out of 245)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Charles River Laboratories (CRL) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Charles River (CRL) delivered earnings and revenue surprises of 7.34% and 4.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Agilon Health (AGL) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Agilon (AGL) delivered earnings and revenue surprises of 33.33% and 5.25%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ELV or DOCS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ELV vs. DOCS: Which Stock Is the Better Value Option?

Zacks Equity Research

ELV or DOCS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ELV vs. DOCS: Which Stock Is the Better Value Option?

Zacks Equity Research

Doximity (DOCS) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Doximity (DOCS) delivered earnings and revenue surprises of 29.41% and 3.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AMN or DOCS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

AMN vs. DOCS: Which Stock Is the Better Value Option?

Zacks Equity Research

AMN vs. DOCS: Which Stock Is the Better Value Option?

by Zacks Equity Research

AMN vs. DOCS: Which Stock Is the Better Value Option?

Zacks Equity Research

AMN or DOCS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

AMN vs. DOCS: Which Stock Is the Better Value Option?

Zacks Equity Research

AMN or DOCS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

AMN vs. DOCS: Which Stock Is the Better Value Option?

Zacks Equity Research

AMN vs. DOCS: Which Stock Is the Better Value Option?

by Zacks Equity Research

AMN vs. DOCS: Which Stock Is the Better Value Option?

Zacks Equity Research

Doximity (DOCS) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Doximity (DOCS) delivered earnings and revenue surprises of 6.25% and 2.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bright Health Group (BHG) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Bright Health (BHG) delivered earnings and revenue surprises of 12.50% and 8.52%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Surgery Partners (SGRY) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Surgery Partners (SGRY) delivered earnings and revenue surprises of -150% and 0.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Progyny (PGNY) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Progyny (PGNY) delivered earnings and revenue surprises of 160% and 5.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Doximity (DOCS) Q2 Earnings Expected to Decline

by Zacks Equity Research

Doximity (DOCS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

AMN or DOCS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

AMN vs. DOCS: Which Stock Is the Better Value Option?

Zacks Equity Research

Why Doximity (DOCS) Could Beat Earnings Estimates Again

by Zacks Equity Research

Doximity (DOCS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

AMN vs. DOCS: Which Stock Is the Better Value Option?

by Zacks Equity Research

AMN vs. DOCS: Which Stock Is the Better Value Option?

Zacks Equity Research

HealthEquity (HQY) Moves 5.3% Higher: Will This Strength Last?

by Zacks Equity Research

HealthEquity (HQY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Zacks Equity Research

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Zacks Equity Research

AMN or DOCS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

AMN vs. DOCS: Which Stock Is the Better Value Option?

Zacks Equity Research

AMN vs. DOCS: Which Stock Is the Better Value Option?

by Zacks Equity Research

AMN vs. DOCS: Which Stock Is the Better Value Option?

Zacks Equity Research

BLCO vs. DOCS: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

BLCO vs. DOCS: Which Stock Is the Better Value Option?

Zacks Equity Research

Doximity (DOCS) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Doximity (DOCS) delivered earnings and revenue surprises of 27.27% and 1.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?